Antibody drug conjugate: the “biological missile” for targeted cancer therapy Article Open access 22 March 2022 Homogeneous multi-payload antibody–drug conjugates Article 17 May 2024 References Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody–drug conjugates: the la...
Recently, trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC), demonstrated superior outcomes compared with treatment of physicians choice (TPC) in this population. Other ADCs have also shown encouraging results, including sacituzumab govitecan (SG), MRG002, and RC48-ADC. Hence, ...
Although antibody–drug conjugate (ADC) or immune checkpoint inhibitors (ICIs) alone fosters hope for the treatment of cancer, the effect of single drug treatment is limited and the safety profile of ADC and ICI therapy remains unclear. This meta-analysis aimed to examine the efficacy and safety...
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate 2022, Pharmaceutics Novel adcs and strategies to overcome resistance to anti-her2 adcs 2022, Cancers View all citing articles on Scopus Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia ...
In the recent past, attempts have been made to conjugate antibodies with polymeric and lipid nanoparticles (LNPs) as carriers for oncology drugs, but no drugs have been approved yet. Despite the challenges, the innovation continues as more drugs enter clinical trials.15,16The...
A Novel Anti-HER2 Anthracycline-Based Antibody-Drug Conjugate Induces Adaptive Anti-Tumor Immunity and Potentiates PD-1 Blockade in Breast Cancer. J. Immunother. Cancer 2019, 7, 16. [Google Scholar] [CrossRef] [PubMed] Iwata, T.N.; Ishii, C.; Ishida, S.; Ogitani, Y.; Wada, T.; ...
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physician
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate AnupamaSamantasinghar, ...Kyung HyunChoi, inBiomedicine & Pharmacotherapy, 2023 1Introduction Antibody Drug Conjugate(ADC) is an emerging class of potent biological drugs that combine a highly potent cytotoxic ...
Antibody Conjugate Therapeutics: Challenges and Potential Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed towa... BA Teicher,RVJ Chari - 《Clinical Cancer Research An Official Journal of the American...
In 2000, the launch of Mylotarg from Pfizer marked the debut ofantibody drug conjugate (ADC), a complex that couples a cytotoxic small molecule drug to a monoclonal antibody via a rationally constructed linker to selectively deliver an effective cytotoxic drug into the tumor. During the eleven ye...